YU2704A - 2- (3, 5-BIS-TRIFLUORMETIL-FENIL) -N-[6-(1, 1-DIOKSO-1λ6-TI0M0RF0LIN-4-IL)-4-(2-METIL- ILI 4-FLUOR-2-METIL- SUPSTITUISAN) -FENIL-PIRIDIN-3-IL]-N-METIL-IZOBUTIRAMID - Google Patents
2- (3, 5-BIS-TRIFLUORMETIL-FENIL) -N-[6-(1, 1-DIOKSO-1λ6-TI0M0RF0LIN-4-IL)-4-(2-METIL- ILI 4-FLUOR-2-METIL- SUPSTITUISAN) -FENIL-PIRIDIN-3-IL]-N-METIL-IZOBUTIRAMIDInfo
- Publication number
- YU2704A YU2704A YU2704A YUP2704A YU2704A YU 2704 A YU2704 A YU 2704A YU 2704 A YU2704 A YU 2704A YU P2704 A YUP2704 A YU P2704A YU 2704 A YU2704 A YU 2704A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- methyl
- phenyl
- isobutyramide
- thiomorpholin
- dioxo
- Prior art date
Links
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- VJYRMMZALMMXPM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-(1,1-dioxo-1,4-thiazinan-4-yl)-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCS(=O)(=O)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VJYRMMZALMMXPM-UHFFFAOYSA-N 0.000 abstract 1
- PSFZPLRNIVTYMJ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-(1,1-dioxo-1,4-thiazinan-4-yl)-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCS(=O)(=O)CC2)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PSFZPLRNIVTYMJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021957 Ocular injury Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000012545 Psychophysiologic disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000036427 bronchial hyperreactivity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000003152 motion sickness Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Ovaj pronalazak se odnosi na jedinjenja 2-(3,5-bis-trifluormetil-fenil)-N-[6-(1,1-dsiokso-1λ6-tiomorfolin-4-il)-4-o-tolil-piridin-3-il]-N-metil-izobutiramid i 2-(3,5-bis-trifluormetil-fenil)-N-[6-(1,1-dsiokso-1λ6-tiomorfolin-4-il)-4-(4-fluor-2-metil-fenil)-piridin-3-il]-N-metil-iobutiramid, koja se mogu primeniti za lecenje migrene, reumatoidnog artritisa, astme, bronhijalne hiperaktivnosti, zapaljive bolesti creva (utrobe) ili za lecenje poremecaja ukljucujuci Parkinsonovu bolest, briznost (anksioznost), depresiju, bol, glavobolju, Alchajmerovu bolest, multipla sklerozu, edeme, alergijski rinitis, Kronovu bolest, povredu oka, ocne zapaljive bolesti, psihozu, bolesti kretanja, indukovano povracanje, emezu, nezadrzavanje mokrenja, psihoimunoloske ili psihosomatske poremecaje, rak (kancer), simptome uskracivanja adiktivnih lekova (droga) iz opijata ili nikotina, traumatsku povredu mozga ili benignu prostatsku hiperplaziju.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01118412 | 2001-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU2704A true YU2704A (sh) | 2006-08-17 |
Family
ID=8178193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU2704A YU2704A (sh) | 2001-07-31 | 2002-07-26 | 2- (3, 5-BIS-TRIFLUORMETIL-FENIL) -N-[6-(1, 1-DIOKSO-1λ6-TI0M0RF0LIN-4-IL)-4-(2-METIL- ILI 4-FLUOR-2-METIL- SUPSTITUISAN) -FENIL-PIRIDIN-3-IL]-N-METIL-IZOBUTIRAMID |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6849624B2 (sh) |
| EP (1) | EP1414525B1 (sh) |
| JP (1) | JP4700908B2 (sh) |
| KR (1) | KR100577101B1 (sh) |
| CN (1) | CN1289497C (sh) |
| AR (1) | AR034921A1 (sh) |
| AT (1) | ATE430600T1 (sh) |
| BR (1) | BR0211523A (sh) |
| CA (1) | CA2452502C (sh) |
| DE (1) | DE60232246D1 (sh) |
| EA (1) | EA006238B1 (sh) |
| EC (1) | ECSP044963A (sh) |
| ES (1) | ES2324209T3 (sh) |
| GT (1) | GT200200159A (sh) |
| HK (1) | HK1069136A1 (sh) |
| HR (1) | HRP20040039A2 (sh) |
| HU (1) | HUP0400398A3 (sh) |
| MA (1) | MA27055A1 (sh) |
| MX (1) | MXPA04000917A (sh) |
| MY (1) | MY128464A (sh) |
| NO (1) | NO20040404L (sh) |
| NZ (1) | NZ530579A (sh) |
| PA (1) | PA8551601A1 (sh) |
| PE (1) | PE20030276A1 (sh) |
| PL (1) | PL366986A1 (sh) |
| UA (1) | UA77685C2 (sh) |
| UY (1) | UY27403A1 (sh) |
| WO (1) | WO2003011860A2 (sh) |
| YU (1) | YU2704A (sh) |
| ZA (1) | ZA200400652B (sh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100599134B1 (ko) * | 2001-04-23 | 2006-07-12 | 에프. 호프만-라 로슈 아게 | 양성 전립선 비대증에 대한 ｎｋ-1 수용체 길항물질의 용도 |
| SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| ES2285233T3 (es) | 2002-12-20 | 2007-11-16 | Niconovum Ab | Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable. |
| ATE366576T1 (de) * | 2003-01-31 | 2007-08-15 | Hoffmann La Roche | Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6- |
| JP4580426B2 (ja) | 2004-07-06 | 2010-11-10 | エフ．ホフマン−ラ ロシュ アーゲー | Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法 |
| CA2601935C (en) * | 2005-02-22 | 2013-04-09 | F. Hoffmann-La Roche Ag | Nk1 antagonists |
| KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
| WO2007104573A2 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| US10383894B2 (en) * | 2010-03-17 | 2019-08-20 | Lutran Industries, Inc. | Human medicinal treatment using salt of peroxymonosulfuric acid |
| KR20160078997A (ko) | 2013-11-08 | 2016-07-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 카복시메틸피페리딘 유도체 |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| US10463655B2 (en) | 2015-03-04 | 2019-11-05 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| CN112218636A (zh) * | 2018-06-08 | 2021-01-12 | 万达制药公司 | 使用川地匹坦进行治疗的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6435115A (en) * | 1987-07-31 | 1989-02-06 | Nippon Seiko Kk | Bearing device |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| BR9408442A (pt) | 1993-12-29 | 1997-08-05 | Merck Sharp & Dohme | Composto composição farmacêutica processos para tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquiquininas e para a preparação do composto e de uso do composto |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| ATE496032T1 (de) | 1999-02-24 | 2011-02-15 | Hoffmann La Roche | 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten |
| KR100599134B1 (ko) * | 2001-04-23 | 2006-07-12 | 에프. 호프만-라 로슈 아게 | 양성 전립선 비대증에 대한 ｎｋ-1 수용체 길항물질의 용도 |
-
2002
- 2002-07-17 US US10/196,795 patent/US6849624B2/en not_active Expired - Fee Related
- 2002-07-25 PE PE2002000667A patent/PE20030276A1/es not_active Application Discontinuation
- 2002-07-26 KR KR1020047001322A patent/KR100577101B1/ko not_active IP Right Cessation
- 2002-07-26 CN CNB028151100A patent/CN1289497C/zh not_active Expired - Fee Related
- 2002-07-26 MX MXPA04000917A patent/MXPA04000917A/es active IP Right Grant
- 2002-07-26 UA UA2004021462A patent/UA77685C2/uk unknown
- 2002-07-26 PA PA20028551601A patent/PA8551601A1/es unknown
- 2002-07-26 WO PCT/EP2002/008311 patent/WO2003011860A2/en active IP Right Grant
- 2002-07-26 JP JP2003517052A patent/JP4700908B2/ja not_active Expired - Fee Related
- 2002-07-26 HU HU0400398A patent/HUP0400398A3/hu unknown
- 2002-07-26 EA EA200400109A patent/EA006238B1/ru not_active IP Right Cessation
- 2002-07-26 NZ NZ530579A patent/NZ530579A/en unknown
- 2002-07-26 CA CA2452502A patent/CA2452502C/en not_active Expired - Fee Related
- 2002-07-26 AT AT02791471T patent/ATE430600T1/de active
- 2002-07-26 ES ES02791471T patent/ES2324209T3/es not_active Expired - Lifetime
- 2002-07-26 BR BR0211523-9A patent/BR0211523A/pt not_active Application Discontinuation
- 2002-07-26 YU YU2704A patent/YU2704A/sh unknown
- 2002-07-26 EP EP02791471A patent/EP1414525B1/en not_active Expired - Lifetime
- 2002-07-26 DE DE60232246T patent/DE60232246D1/de not_active Expired - Lifetime
- 2002-07-26 PL PL02366986A patent/PL366986A1/xx not_active Application Discontinuation
- 2002-07-29 AR ARP020102847A patent/AR034921A1/es not_active Application Discontinuation
- 2002-07-29 MY MYPI20022848A patent/MY128464A/en unknown
- 2002-07-30 UY UY27403A patent/UY27403A1/es not_active Application Discontinuation
- 2002-07-31 GT GT200200159A patent/GT200200159A/es unknown
-
2004
- 2004-01-15 HR HR20040039A patent/HRP20040039A2/hr not_active Application Discontinuation
- 2004-01-27 ZA ZA200400652A patent/ZA200400652B/xx unknown
- 2004-01-29 EC EC2004004963A patent/ECSP044963A/es unknown
- 2004-01-29 NO NO20040404A patent/NO20040404L/no unknown
- 2004-01-30 MA MA27507A patent/MA27055A1/fr unknown
-
2005
- 2005-02-28 HK HK05101662A patent/HK1069136A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU2704A (sh) | 2- (3, 5-BIS-TRIFLUORMETIL-FENIL) -N-[6-(1, 1-DIOKSO-1λ6-TI0M0RF0LIN-4-IL)-4-(2-METIL- ILI 4-FLUOR-2-METIL- SUPSTITUISAN) -FENIL-PIRIDIN-3-IL]-N-METIL-IZOBUTIRAMID | |
| GR3032506T3 (en) | 3-aryl-2-isoxazolines as antiinflammatory agents | |
| ES2104424T3 (es) | Compuestos de isoxazolina como agentes antiinflamatorios. | |
| WO2007038209A3 (en) | Fused tetracyclic mglur1 antagonists as therapeutic agents | |
| SG155943A1 (en) | Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors | |
| HK1060131A1 (en) | N-(3,3-dimethylindolin-6-yl) (2-Ä(4-pyridylmethyl)aminoÜ (3-pyridyl))carboxamide and pharmaceutical compositions thereof | |
| BRPI0509391A (pt) | piridonas substituìdos como inibidores de poli(adp-ribose) polimerase (parp) | |
| DE69332762D1 (de) | Cathecoldiether als selektive pde iv hemmungsmittel | |
| CY1108745T1 (el) | Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων | |
| WO2007067511A3 (en) | Morpholine carboxamide prokineticin receptor antagonists | |
| MY127426A (en) | 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide | |
| TW200738733A (en) | Fused tricyclic mGluR1 antagonists as therapeutic agents | |
| JP2005500354A5 (sh) | ||
| IL158704A0 (en) | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| TW200740826A (en) | Fused tricyclic mGluR1 antagonists as therapeutic agents | |
| IL158703A0 (en) | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| IL158632A0 (en) | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| CA2514037A1 (en) | Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide | |
| IL158695A0 (en) | 4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| IL147953A0 (en) | Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-carboxamide, having anti-epileptic, neurological, and cns activity, and method for their preparation | |
| WO2002076437A3 (en) | Methods for treating neurodegenerative diseases including alzheimer's | |
| TH63562A (th) | 2-(3,5-บิส-ไตรฟลูออโรเมทธิล-ฟีนิล)-n-[6-(1, 1-ไดออกโซ-1) 6-ไธโอมอร์โฟลีน-4-อิล)-4-(2-เมทธิล หรือ 4-ฟลูออโร-2-เมทธิลที่ถูกแทนที่)ฟีนิล-ไพริดีน-3-อิล]-n-เมทธิล-ไอโซบิวไทราไมด์ |